Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (195)	3/16/2004 5:58:25 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

Bad timing ? 09.03.2004 11:49 GPC Biotech stellt Entwicklung von Bryostatin ein München/Frankfurt (vwd) - Die GPC Biotech AG, Martinsried, hat die Entwicklung der beiden Medikamenten-Kandidaten Bryostatin-1 und Bryologs eingestellt. Für Bryostatin-1 sei bislang kein Verabreichungsschema gefunden worden, das eine Wirksamkeit des Präparats ohne akzeptable Nebenwirkungen ermöglicht hätte, teilte Vorstandsvorsitzender Bernd R. Seizinger am Dienstag in Frankfurt mit. Auch der Wirkstoff Bryologs habe keine ausreichende Wirksamkeit gegen Tumoraktivitäten gezeigt. On its pipeline, GPC Biotech said it has decided to discontinue development of Bryostatin-1, a therapeutic oncology compound. GPC in-licensed Bryostatin-1 from Arizona State University in 2001. This is a little bit strange as there are a fair number of NCI-sponsored trials ongoing for the drug. I suppose that CTIC would be happy to in-lincense this drug if it is available. Erik

To: tuck who wrote (195)	3/17/2004 6:39:20 PM
From: Biomaven	Respond to of 946

Well it may be no more than coincidence, but I was just reading about NADPH oxidase and cancer in the context of MSHL's phenoxodiol: marshalledwardsinc.com It may conceivably be that the variant form (dubbed tNOX by the Morre's) is more susceptible to producing ROS in the presence of arsenic than the regular CNOX. Here's some more on tNOX: Cancer Lett. 2003 Feb 20;190(2):135-41. Related Articles, Links Sera from cancer patients contain two oscillating ECTO-NOX activities with different period lengths. Wang S, Morre DM, Morre DJ. Department of Foods and Nutrition, Purdue University, West Lafayette, IN, USA. ECTO-NOX protein's are cell surface-associated and growth-related hydroquinone oxidases with both protein disulfide-thiol interchange activity and the capacity to oxidize NAD(P)H. The activities of these ECTO-NOX proteins are not steady state but fluctuate to create a repeating pattern of oscillations. Two forms of ECTO-NOX activities have been distinguished. The constitutive ECTO-NOX (CNOX), is hormone responsive and refractory to quinone-site inhibitors. A tumor-associated NOX (tNOX) is unregulated, refractory to hormones and growth factors and responds to quinone-site inhibitors. CNOX proteins are widely distributed and exhibit oscillations in enzymatic activity with a period length of 24 min. tNOX proteins are cancer specific and exhibit oscillations with a period length of about 22 min. Our findings now demonstrate the presence of the novel oscillating tNOX activity in sera of patients with cancer whereas the constitutive NOX of non-cancer cells is present in sera of both cancer patients and healthy volunteers. We conclude that ECTO-NOX proteins in sera exhibit oscillatory characteristics similar to those of ECTO-NOX forms of the cell surface.